Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow, Mitochondrial Function and Leg Performance in Patients With Peripheral Artery Disease

Next Previous
Search
Trial Profile

Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow, Mitochondrial Function and Leg Performance in Patients With Peripheral Artery Disease

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sapropterin (Primary)
  • Indications Peripheral arterial disorders
  • Focus Therapeutic Use

Most Recent Events

  • 12 Aug 2023 Planned End Date changed from 1 Oct 2020 to 1 Oct 2019.
  • 12 Aug 2023 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2019.
  • 28 Oct 2020 Status changed from not yet recruiting to withdrawn prior to enrolment due to change in operating plans.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top